ClinicalTrials.gg
CompletedNCT03653546BMUpdated Sep 10, 2025

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

A Phase 2/3 interventional study of AZD3759 and Erlotinib in Non-small Cell Lung Cancer, EGFR Gene Mutation and Brain Metastases, sponsored by Alpha Biopharma (Jiangsu) Co., Ltd.. Completed at 58 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Alpha Biopharma (Jiangsu) Co., Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
492
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Enrollment
212th of 1,594
492 · median 100
Started
2018
with 89 others
Phase 2/3
38 of 1,881
16 open now
Registered
495th of 1,881
by date

Among the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 212th largest by enrollment of the 1,594 interventional ones that give a count, is one of 90 that started in 2018, is one of 38 in phase 2/3, and was the 495th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with advanced EGFR mutation positive non-small cell lung cancer (NSCLC) with Central Nervous System (CNS) metastasis

Read the detailed description

This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs. Erlotinib or Gefitinib treatment in patients with advanced EGFR mutation positive NSCLC with CNS metastases.

Eligible patients with documented EGFR mutation+ (L858R and/or Exon 19Del) TKI-naïve advanced NSCLC and documented intracranial disease will be enrolled.

03

Conditions studied

  • Non-small Cell Lung Cancer
  • EGFR Gene Mutation
  • Brain Metastases

Keywords

  • Central Nervous System Metastases
  • Respiratory Tract Diseases
  • EGFR
  • Exon 19Del
  • L858R
  • Lung Neoplasm
  • Carcinoma, Non-Small-Cell Lung
  • Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Properly completed patient
  2. Male or female aged at least 18 years
  3. or cytologically confirmed diagnosis of NSCLC with activating EGFR mutations including L858R and/or Exon19Del. EGFR mutation status will be determined by local or central laboratory testing on tumour tissue or plasma utilizing a validated methodology which has been approved by the regulatory authority.
  4. No prior treatment with chemotherapy, EGFR-TKIs, or biological therapies that are considered treatment for advanced NSCLC.
  5. All patients must have a documented diagnosis of advanced (Stage IV) NSCLC with Magnetic Resonance Imaging (MRI) documented that include brain metastases (BM). BM + patients with co- existent are eligible for the study.
  6. Eligible patients are not candidates for definitive surgical resection or radiation of all lesions in the opinion of the treating physician.
  7. All patients must be stable without any systemic (oral or parenteral) or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled non-absorbable and topical corticosteroid use are permitted as indicated.
  8. Patients may have prior placement of a properly functioning CNS shunt or Ommaya reservoir.
  9. (ECOG) performance status 0 to 1 with no deterioration over the previous 2 weeks.
  10. Women of and male subjects shall agree to take medically acceptable measures while on study treatment and for 3 months following completion of study treatment. All women of child-bearing potential must have a negative blood pregnancy test at screening.
  11. (a) For Patients with measurable CNS lesions must have AT LEAST ONE site of CNS lesion, which was not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter by MRI and which is suitable for accurate repeated measurements. Measurable extracranial disease is not required. (b) For Patients with non-measurable CNS lesions must have AT LEAST ONE extracranial lesion, which has not been previously irradiated, within the screening period that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) by CT/MRI and are suitable for accurate repeated measurement.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
492 participants (actual)

Study arms

  • Experimental
    AZD3759 Group

    AZD3759 group will receive a 200 mg twice daily dose of AZD3759

    Drug: AZD3759

  • Active comparator
    Erlotinib or Gefitinib Group

    SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D

    Drug: Erlotinib · Drug: Gefitinib

Interventions

  • AZD3759 200mg PO BID.

  • SoC EGFRTKI Erlotinib 150 mg PO Q.D

    Also known as: Tarceva

  • SoC EGFRTKI Gefitinib 250 mg PO Q.D

    Also known as: Iressa

06

What researchers measure

Primary outcomes

  1. PFS assessed by Blinded Independent Central Radiological

    To assess if first line treatment with AZD3759 results in significant PFS efficacy compared to Gefitinib or Erlotinib as determined by Blinded Independent Central Radiological (BICR) review using RECIST 1.1.

    Time frame: 48 months

Secondary outcomes

  1. PFS assess by investigator

    Investigator assessment of PFS using RECIST 1.1

    Time frame: 48 months

  2. Intracranial PFS (iPFS) assessed by investigator

    Intracranial PFS (iPFS) assessed by investigator using RECIST 1.1

    Time frame: 48 months

  3. Intracranial PFS (iPFS) assessed by BICR

    Intracranial PFS (iPFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1

    Time frame: 48 months

  4. Extracranial PFS (ePFS) assessed by investigator

    Extracranial PFS (ePFS) assessed by investigator using RECIST 1.1

    Time frame: 48 months

  5. Extracranial PFS (ePFS) assessed by BICR

    Extracranial PFS (ePFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1

    Time frame: 48 months

  6. Objective Response Rate (ORR) assessed by investigator using RECIST 1.1

    Objective Response Rate (ORR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1

    Time frame: 48 months

  7. Disease Control Rate (DCR) assessed by investigator using RECIST 1.1

    Disease Control Rate (DCR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1

    Time frame: 48 months

  8. Duration of Response (DoR) assessed by investigator using RECIST 1.1

    Duration of Response (DoR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1

    Time frame: 48 months

  9. Overall ORR assessed by investigator using RECIST 1.1

    Overall ORR assessed by investigator using RECIST 1.1

    Time frame: 48 months

  10. Overall DCR assessed by investigator using RECIST 1.1

    Overall DCR assessed by investigator using RECIST 1.1

    Time frame: 48 months

  11. Overall DoR assessed by investigator using RECIST 1.1

    Overall DoR assessed by investigator using RECIST 1.1

    Time frame: 48 months

  12. ORR for Intracranial lesions assessed by investigator using RANO-BM

    ORR for Intracranial lesions assessed by investigator using RANO-BM

    Time frame: 48 months

  13. DCR for Intracranial lesions assessed by investigator using RANO-BM

    DCR for Intracranial lesions assessed by investigator using RANO-BM

    Time frame: 48 months

  14. DoR for Intracranial lesions assessed by investigator using RANO-BM

    DoR for Intracranial lesions assessed by investigator using RANO-BM

    Time frame: 48 months

  15. Overall Survival

    Overall Survival

    Time frame: 48 months

  16. Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30).

    The 30-items questionnaire measures cancer patients' functioning and symptoms. The scale range of EORTC QLQ-C30 is 30-126. Lower values represent a better outcome.

    Time frame: 48 months

  17. Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire BN20 (EORTC QLQ-BN20).

    The 20-items questionnaire was used among brain cancer patients. The scale range of EORTC BN20 is 20-80. Lower values represent a better outcome.

    Time frame: 48 months

  18. Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)

    Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)

    Time frame: 48 months

  19. Neurological function improvement rate assessed by RANO-BM criteria

    Neurological function improvement rate assessed by RANO-BM criteria

    Time frame: 48 months

  20. Number of participants with treatment-related Adverse Events as assessed by CTCAE v5.0

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: 48 months

  21. Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0

    Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0

    Time frame: 48 months

  22. Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0

    Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0

    Time frame: 48 months

  23. Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0

    Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0

    Time frame: 48 months

  24. Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0

    Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0

    Time frame: 48 months

  25. Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.

    Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.

    Time frame: 48 months

  26. Systolic and Diastolic Blood Pressure assessed during the study period.

    Systolic and Diastolic Blood Pressure assessed during the study period.

    Time frame: 48 months

  27. Pulse rate assessed during the study period.

    Pulse rate to assessed during the study period.

    Time frame: 48 months

  28. Body temperature assessed during the study period.

    Body temperature assessed during the study period.

    Time frame: 48 months

  29. PFS assess by BICR

    Blinded Independent Central Radiological (BICR) assessment of PFS using modified RECIST 1.1.

    Time frame: 48 months

Other outcomes

  1. Pop-PK analysis

    Population pharmacokinetic analysis

    Time frame: 48 months

  2. Exposure-Response analysis

    explore the correlation in exposure and efficacy, exposure and safety in the Study

    Time frame: 48 months

07

Study locations

58 sites
  • China site
    Hefei, Anhui 230001, China
  • China site
    Chongqing, China 400037, China
  • China site
    Fuzhou, Fujian 350014, China
  • China site
    Xiamen, Fujian 361003, China
  • China site
    Guangzhou, Guangdong 510080, China
  • China site
    Guangzhou, Guangdong 510180, China
  • China site
    Haerbin, Heilongjiang 150081, China
  • China site
    Zhengzhou, Henan 450008, China
  • China site
    Zhengzhou, Henan 450052, China
  • China site
    Wuhan, Hubei 430022, China
  • China site
    Wuhan, Hubei 430030, China
  • China site
    Wuhan, Hubei 430079, China
  • China site
    Yichang, Hubei 443003, China
  • China site
    Changsha, Hunan 410013, China
  • China site
    Nanjing, Jiangsu 210002, China
  • China site
    Nanjing, Jiangsu 210009, China
  • China site
    Suzhou, Jiangsu 215004, China
  • China site
    Wuxi, Jiangsu 214062, China
  • China site
    Xuzhou, Jiangsu 221002, China
  • China site
    Yangzhou, Jiangsu 225001, China
  • China site
    Changchun, Jilin 130012, China
  • China site
    Changchun, Jilin 130021, China
  • China site
    Xi'an, Shaanxi 710061, China
  • China site 0123
    Jinan, Shandong 250117, China
  • China site
    Linyi, Shandong 276000, China
  • China site
    Weifang, Shandong 261000, China
  • China site
    Yantai, Shandong 264000, China
  • China site
    Chengdu, Sichuan 610041, China
  • China site
    Kunming, Yunnan 650118, China
  • China site
    Hangzhou, Zhejiang 310003, China
  • China site
    Hangzhou, Zhejiang 310022, China
  • China site
    Hangzhou, Zhejiang 311100, China
  • China site
    Beijing, 100021, China
  • China site
    Beijing, 100071, China
  • China site
    Beijing, 100142, China
  • China site
    Beijing, 100730, China
  • China site
    Chongqing, 400030, China
  • China site
    Chongqing, 400042, China
  • China site
    Shanghai, 200030, China
  • China site
    Shanghai, 200032, China
  • China site
    Tianjin, 300052, China
  • Singapore site
    Singapore, 308433, Singapore
  • Korea site
    Daegu, 42415, South Korea
  • Korea site
    Gyeonggi-do, 16247, South Korea
  • Korea site
    Gyeongsang, 52727, South Korea
  • Korea site
    Incheon, 21565, South Korea
  • Korea Site
    Seoul, 03080, South Korea
  • Korea site
    Seoul, 05368, South Korea
  • Korea Site
    Seoul, 06351, South Korea
  • Korea site
    Seoul, 06591, South Korea
  • Korea site
    Seoul, 07061, South Korea
  • Korea site
    Suwon, 16499, South Korea
  • Korea Site
    Taebuk, 28644, South Korea
  • Korea site
    Ulsan, 44033, South Korea
  • Taiwan site
    Taichung, 407, Taiwan
  • Taiwan site
    Tainan, 704, Taiwan
  • Taiwan site
    Taipei, 100, Taiwan
  • Taiwan site
    Taoyuan, 333, Taiwan
08

References and documents

Publications

  • Zhou Q, Yu Y, Xing L, Cheng Y, Wang Y, Pan Y, Fan Y, Shi J, Zhang G, Cui J, Zhou J, Song Y, Zhuang W, Ma Z, Hu Y, Li G, Dong X, Feng J, Lu S, Wu J, Li J, Zhang L, Wang D, Xu X, Yang TY, Yang N, Guo Y, Zhao J, Yao Y, Zhong D, Xia B, Yang CT, Zhu B, Sun P, Shim BY, Chen Y, Wang Z, Ahn MJ, Wang J, Wu YL. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial. Med. 2025 Jan 10;6(1):100513. doi: 10.1016/j.medj.2024.09.002. Epub 2024 Oct 9. PubMed 39389055 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jul 2022, 44 months.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2018
First posted
Aug 31, 2018
StartActual
Oct 29, 2018
Primary completionActual
Jul 12, 2022
CompletionActual
Jul 12, 2022
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03653546
Lead sponsor
Alpha Biopharma (Jiangsu) Co., Ltd.
Responsible party
Sponsor
First posted
Aug 31, 2018
Start date
Oct 29, 2018
Primary completion
Jul 12, 2022
Completion
Jul 12, 2022
Last update
Sep 10, 2025

Study contacts

Yilong Wu, M.D.
study chair · Guangdong Provincial People's Hospital
Myung-Ju Ahn, M.D.
principal investigator · Samsung Medical Center
Jie Wang, M.D.
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Qing Zhou, M.D.
principal investigator · Guangdong Provincial People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD3759

Start the discussion